==== Front J Hematol Oncol J Hematol Oncol Journal of Hematology & Oncology 1756-8722 BioMed Central London 1005 10.1186/s13045-020-01005-x Review RNA sequencing: new technologies and applications in cancer research Hong Mingye 1 Tao Shuang 2 Zhang Ling 3 Diao Li-Ting 2 Huang Xuanmei 1 Huang Shaohui 1 Xie Shu-Juan 2 Xiao Zhen-Dong xiaozhd@mail2.sysu.edu.cn 2 http://orcid.org/0000-0001-9731-2737Zhang Hua huazhang@gdmu.edu.cn 1 1 grid.410560.60000 0004 1760 3078Institute of Laboratory Medicine, Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, School of Medical Technology, Guangdong Medical University, Dongguan, 523808 China 2 grid.412558.f0000 0004 1762 1794Biotherapy Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630 China 3 grid.267308.80000 0000 9206 2401Health Science Center, The University of Texas, Houston, 77030 USA 4 12 2020 4 12 2020 2020 13 16631 10 2020 22 11 2020 © The Author(s) 2020Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Over the past few decades, RNA sequencing has significantly progressed, becoming a paramount approach for transcriptome profiling. The revolution from bulk RNA sequencing to single-molecular, single-cell and spatial transcriptome approaches has enabled increasingly accurate, individual cell resolution incorporated with spatial information. Cancer, a major malignant and heterogeneous lethal disease, remains an enormous challenge in medical research and clinical treatment. As a vital tool, RNA sequencing has been utilized in many aspects of cancer research and therapy, including biomarker discovery and characterization of cancer heterogeneity and evolution, drug resistance, cancer immune microenvironment and immunotherapy, cancer neoantigens and so on. In this review, the latest studies on RNA sequencing technology and their applications in cancer are summarized, and future challenges and opportunities for RNA sequencing technology in cancer applications are discussed. Keywords RNA sequencingApplicationCancerissue-copyright-statement© The Author(s) 2020 ==== Body Background Cancer remains one of the major malignant diseases that endangers human life and health and comprises complex biological systems that require accurate and comprehensive analysis. Since the first appearance of high-throughput sequencing in 2005 [1], it has become possible to understand life activities at the molecular level and to conduct detailed research to elucidate the genome and transcriptome. As an essential part of high-throughput sequencing, RNA sequencing (RNA-seq), especially single-cell RNA sequencing (scRNA-seq), provides biological information on a single tumor cell, analyzes the determinants of intratumor expression heterogeneity and identifies the molecular basis of formation of many oncological diseases [2, 3]. Thus, RNA sequencing offers invaluable insights for cancer research and treatment. With the advent of the era of precision medicine, RNA sequencing will be widely used for research on many different types of cancer. This review summarizes the history of the development of RNA sequencing and focuses on the latest studies of RNA sequencing technology in cancer applications, especially single-cell RNA sequencing and spatial transcriptome sequencing. In addition, we provide a general introduction to the current bioinformatics analysis tools used for RNA sequencing and discuss future challenges and opportunities for RNA sequencing technology in cancer applications. The development of RNA sequencing technologies It was not until 1953 when Watson and Crick proposed the double-helix structure did people truly realize at the molecular level that the essence of life is the result of gene interactions [4]. The continuous development of RNA sequencing has ushered transcriptome analysis into a new era, with higher efficiency and lower cost. The timeline of RNA sequencing technologies is shown in Fig. 1.Fig. 1 The development timeline of RNA sequencing technologies The first-generation sequencing technology is also called Sanger sequencing. The chain termination method was initiated by Sanger in 1977, followed by the chemical degradation method developed by Maxam and Gilbert [5, 6]. The same year, Sanger determined the 5368 bp genome of phage φX174, which is the first DNA genome sequenced [7]. The DNA microarray has aided significant progress in many fields since it was first introduced. However, microarrays require prior knowledge of gene sequences and are unable to identify novel gene expression [8]. After the first high-throughput sequencing platform appeared in 2005 [1], multiple next-generation sequencing platforms followed (Table 1, Figs. 2, 3). The accuracy and reproducibility among different platforms depended on several factors, including the inherent features of the platform and the corresponding analysis pipelines [9, 10]. Pyrosequencing that was no longer supported after 2016, developed by 454 Life Sciences, used a “sequencing by synthesis” method [1, 11–13]. The ion torrent sequencing platform is also based on the “sequencing by synthesis” method, which outperforms pyrosequencing with respect to sensitivity. SOLiD (Sequencing by Oligonucleotide Ligation and Detection) exhibits high accuracy, as each base is sequenced twice, but the read length is short [11–13]. DNBS (DNA nanoball sequencing) enables large collection of DNA nanoballs for simultaneous sequencing. Illumina-based sequencing technology represents a “reversible terminator sequencing” method. High-throughput sequencing has the advantage of fast speed, low sequencing cost and high accuracy, otherwise known as next-generation sequencing (NGS). Compared to microarray, it can detect unknown gene expression sequences but is time intensive [14].Table 1 Comparison of different RNA sequencing platforms Platform Company Read length(bases) Run time Volume per run Cost Template preparation Sequencing chemistry The first-generation sequencing Sanger Life sciences 800 bp 2 h 1 read $2400 per million bases Bacterial cloning Dideoxynucleosides terminator The next-generation sequencing Roche 454 pyrosequencing 454 Life sciences 700 bp  < 24 h 0.7 Gb $10 per million bases Emulsion PCR Sequencing by synthesis, pyrosequencing Illumina HiSeq Illumina 100 bp 3–10 days 120–1500 Gb $0.02—$0.07 per million bases Bridge PCR Reversible terminator sequencing Illumina MiSeq Illumina 100 bp 1–2 days 0.3–15 Gb $0.13 per million bases Bridge PCR Reversible terminator sequencing SOLiD Applied biosystems instruments (ABI) 50–75 bp 7–14 days 30 Gb $0.13 per million bases Emulsion PCR Sequencing by ligation DNA nanoball sequencing Complete genomics 440–500 bp 9 days 20–60 Gb $4400/genome Rolling circle replication Hybridization and ligation Ion torrent 454 Life sciences 200–500 bp 4–5 h 660 Mb; 11 Mb $300 to $750 per run Emulsion PCR Sequencing by synthesis The third-generation sequencing SMRT Pacific biosciences  > 900 bp 1-2 h 0.5–1 Gb $2 per million bases No need Sequencing by synthesis Helicos sequencing Helicos biosciences 25–60 bp 8 days 21–35 Gb $0.01 per million bases No need Hybridization and synthesis Nanopore sequencing Oxford nanopore technologies Up to 98 kb 48/72 h Up to 30 Gb  < $1 per million bases No need Nanopore Fig. 2 RNA extraction and template preparation before RNA-sequencing. RNA was extracted from tissues, and after fragmentation, fragmented DNA molecules were converted into cDNA by reverse transcription then amplified by emulsion PCR or bridge PCR to prepare sequencing library Fig. 3 Three kinds of sequencing methods. These methods contain sequencing by synthesis, sequencing by reversible terminator and sequencing by ligation. And their different mechanisms are shown in detail In addition to NGS, there is third-generation sequencing, which allows for long-read sequencing of individual RNA molecules [15]. Single-molecule RNA sequencing enables the generation of full-length cDNA transcripts without clonal amplification or transcript assembly. Thus, third-generation sequencing is free from the shortcomings generated by PCR amplification and read mapping. It can greatly reduce the false positive rate of splice sites and capture the diversity of transcript isoforms [15]. Single-molecule sequencing platforms comprise Pacific Biosciences (PacBio) single-molecule real-time (SMRT) sequencing [16], Helicos single-molecule fluorescent sequencing [17] and Oxford Nanopore Technologies (ONT) nanopore sequencing [18]. Furthermore, RNA-seq recently evolved from bulk sequencing to single-cell sequencing. Single-cell RNA sequencing was first published in 2009 to profile the transcriptome at single-cell resolution [19]. Drop-Seq and InDrop were initially reported in 2015 by analyzing mouse retina cell and embryonic stem cell transcriptomes, identifying novel cell types. Sci-RNA-seq, single-cell combinatorial indexing RNA sequencing, was developed in 2017, and SPLiT-seq (split-pool ligation-based transcriptome sequencing) was first reported in 2018. Both approaches use a combinatorial indexing strategy in which attached RNAs are labeled with barcodes that indicate their cellular origin [20, 21]. Though single-cell data enable single-cell transcriptomics, it may lose spatial information during single-cell isolation. To solve this problem, spatial transcriptomics has emerged. Spatial transcriptomics employs unique positional barcodes to visualize RNA distributions in RNA sequencing of tissue sections and was first published in 2016 [22]. Slide-seq, reported in 2019, uses DNA barcode beads with specific positional information [23]. Geo-seq was introduced in 2017 and integrated scRNA-seq with laser capture microdissection (LCM), which can isolate individual cells [24]. In situ sequencing refers to targeted sequencing of RNA fragments in morphologically preserved tissues or cells without RNA extraction, including in situ cDNA synthesis by padlock probes or stably cross-linked cDNA amplicons in fluorescent in situ RNA sequencing (FISSEQ) and in situ amplification by rolling-circle amplification (RCA) [25, 26]. Furthermore, various new technologies based on RNA-seq have been developed for specific applications. For example, a type of targeted RNA sequencing, CaptureSeq, employs biotinylated oligonucleotide probes and results in the enrichment of certain transcripts to identify gene fusion [27, 28]. Computational analysis of RNA sequencing data Computational analysis tools for RNA sequencing have dramatically increased during the past decade. The choice of a particular tool should be based on the purpose and accuracy of application [29–31]. A general RNA sequencing data analysis process involves the quality control of raw data, read alignment and transcript assembly, expression quantification and differential expression analysis (Fig. 4).Fig. 4 Bioinformatics tools commonly used in RNA-seq data analysis. These tools are primarily used in the four main processes of RNA-seq data analysis, including quality control, read alignment and transcript assembly, expression quantification and differential expression analysis The first step of data analysis is to assess and clean the raw sequencing data, which is usually provided in the form of FASTQ files [32]. Quality control visually reflects the quality of the sequencing and purposefully discards low-quality reads, eliminates poor-quality bases and trims adaptor sequences [31]. Common tools include FASTQ [33], NGSQC [34], RNA-SeQC [35], Trimmomatic [36], PRINSEQ [37] and Soapnuke [38]. The next step is to map the clean reads to either a genome or a transcriptome. There are some mapping tools available, including Tophat2 [39], HISAT2 [40], STAR [41], BWA [42] and Bowtie [43]. After alignment, another type of software, such as Cufflinks [44], StringTie [45], Trinity [46], SOAPdenovoTrans [47] and Trans-AByS [48] can be used to assemble transcripts from short-reads. When the transcript model is established, its expression can be quantified at the gene, transcript and exon levels. Commonly used software for gene-level quantification includes FeatureCount [49] and HTSeq-count [50]. Transcript level quantitative software includes Cufflinks [44], eXpress [51] and RSEM [52]. DEXSeq is a software for exon level quantification [53]. In addition, there are some alignment-free quantification tools such as Kallisto [54], Sailfish [55] and Salmon [56], which have the advantage of marked computational resource saving. After normalizing, an expression matrix is generated, and statistical methods can be used to identify differentially expressed genes. DESeq2 [57] and edgeR [58] are commonly used to perform this task. Applications of RNA-sequencing in cancer research Genomic data, such as RNA-seq, have become widely available due to the popularity of high-throughput sequencing technology [59]. As an important part of next-generation sequencing, RNA sequencing has made great contributions in various fields, especially cancer research, including studies on differential gene expression analysis and cancer biomarkers, cancer heterogeneity and evolution, cancer drug resistance, the cancer microenvironment and immunotherapy, neoantigens, etc. (Fig. 5).Fig. 5 Applications of RNA-seq in differential expression analysis and cancer biomarkers, cancer heterogeneity and drug resistance, cancer immune microenvironment, immunotherapy and neoantigen. a Differential expression analysis by RNA sequencing can identify potential biomarkers, including fusion transcript, lncRNA, miRNA and circRNA. b The heterogeneity and drug resistance of cancer cells identified by RNA-seq. c Novel molecular signature, regulatory protein and unknown subtypes in cancer infiltrating immune cells and potential resistance effector in immunotherapy can be identified by RNA-seq; d Neoantigen profiling by RNA-seq and TCR modification targeted neoantigens Differential gene expression analysis and cancer biomarkers Differential gene expression analysis is one of the most common applications of RNA sequencing [60]. Samples from different backgrounds (different species, tissues and periods) can be used for RNA sequencing to identify differentially expressed genes, revealing their function and potential molecular mechanisms [61]. More importantly, differential gene expression analysis facilitates the discovery of potential cancer biomarkers [62]. Many studies have shown that gene fusions are closely related to oncogenesis and are appreciated as both ideal cancer biomarkers and therapeutic targets [63]. Gene fusions in clinical samples are primarily detected by RNA-CaptureSeq. Compared to whole transcriptome sequencing, RNA-CaptureSeq has significantly higher sequencing depth [27, 64, 65]. It has been reported that the NUP98-PHF23 fusion gene is likely to be a novel therapeutic target in acute myeloid leukemia (AML) [66]. Recently, a variety of recurrent gene fusions, including ESR1-CCDC170, SEC16A-NOTCH1, SEC22B-NOTCH2 and ESR1-YAP1, have been identified in breast cancer, indicating that recurrent gene fusion is one of the key drivers for cancer [67]. Several novel configurations of  BRAF, NTRK3 and RET gene fusions have been identified in colorectal cancer [68]. These fusions may promote the development of malignancy and provide new targets for personalized treatment [68]. In addition, some special genomic factors have been discovered as biomarkers by RNA sequencing, including miRNA, lncRNA and circRNA, which are widely present in various types of cancer [69–71]. A recent example is circRNA_0001178 and circRNA_0000826, which are biomarkers of colorectal cancer metastasis to the liver [72]. By applying both RNA sequencing and small RNA sequencing, a study on pancreatic cancer identified differential expression of simple repetitive sequences (SSRs) and demonstrated that the frequency of SSR motifs changed dramatically, which is expected to become a tumor biomarker [73]. In addition to nucleic acid biomarkers, RNA-seq combined with immunohistochemistry and western blot has also identified certain proteins as cancer biomarkers, such as nuclear COX2 (cyclooxygenase2) in combination with HER2 (human epidermal growth factor receptor type 2), which may serve as potential biomarkers for the diagnosis and prognosis of colorectal cancer [74]. Similar examples identified using RNA-seq profiling analysis include ISG15 (Interferon-stimulated gene 15) in nasopharyngeal carcinoma [75] and DMGDH (dimethylglycine dehydrogenase) in hepatocellular carcinoma [76]. Data-mining analysis of RNA sequencing data and other clinical data has identified that the isoforms of peroxiredoxins also can be expected the prognostic biomarkers for predicting overall survival and relapse-free survival in breast cancer [77]. Increasing differentially expressed genes are being identified by RNA sequencing, and new potential cancer biomarkers are being continuously discovered (Table 2). However, sufficient clinical practice is needed to confirm the diagnostic and predictive applications of these biomarkers in cancer.Table 2 Representative potential biomarkers identified by RNA-seq in cancer Cancer type Biomarker name Biomarker type Up/Down Value References Liver cancer tRNA-ValTAC-3/tRNA-GlyTCC-5/tRNA-ValAAC-5/tRNA-GluCTC-5 tsRNA Up Diagnostic [92] ACVR2B-AS1 LncRNA Up Prognostic/therapeutic target [93] Lung cancer LINC01537 LncRNA Down Prognostic/therapeutic target [94] circFARSA CircRNA Up Noninvasive biomarker [95] LINC01123 LncRNA Up Prognostic/therapeutic target [96] Gastric cancer CTD2510F5.4 LncRNA Up Diagnostic/prognostic [97] MEF2C-AS1/FENDRR LncRNA Down Diagnostic/prognostic [98] Prostate cancer PSLNR LncRNA Down Diagnostic/therapeutic target [99] Colorectal cancer RAMS11 LncRNA Up Therapeutic target [100] CRCAL-1/CRCAL-2 /CRCAL-3/ CRCAL-4 LncRNA Up Therapeutic target [101] Colon cancer AFAP1-AS1 LncRNA Up Prognostic/ therapeutic target [102] Head and neck squamous cell carcinoma LINC00460 LncRNA Up Prognostic [103] HCG22 LncRNA Down Prognostic [104] HOXA11-AS/LINC00964/MALAT1 LncRNA Up Diagnostic [105] Clear cell renal cell carcinomas SLINKY LncRNA Up Prognostic [106] Leukemia LUCAT1 LncRNA Up Therapeutic target [107] circ-HIPK2 CircRNA Down Diagnostic/prognostic [108] RNA-seq could detect early mutations as well as high molecular risk mutations, thus can discover novel cancer biomarkers and potential therapeutic targets, monitoring of diseases and guiding targeted therapy during early treatment decisions. Tumor mutation burden (TMB) is considered as a potential biomarker for immune checkpoint therapy and prognosis [78, 79]. RNA-seq can be used to explore the application value of TMB in diffuse glioma [78]. Through the RNA-seq, MET exon 14 mutation and isocitrate dehydrogenase 1 (IDH1) mutation were identified as new potential therapeutic targets in lung adenocarcinoma and chondrosarcoma patients, respectively [80, 81]. Several studies have shown that RNA sequencing can effectively improve the detection rate on the basis of DNA sequencing, provide more comprehensive detection results and achieve a better curative effect for targeted therapy [82]. In addition, it has been proved that IDH mutation is a good prognostic marker for glioma by RNA-seq [83]. Targeted therapy is also considered to enhance or replace cytotoxic chemotherapy regimen in cancer including AML [84–86]. ScRNA-seq also has some new discoveries in diagnosis. For example, scRNA-seq data can be used to infer copy number variations (CNV) and to distinguish malignant from non-malignant cells. The infer CNV algorithm, which was used in the study of glioblastoma, uses averaging relative expression levels over large genomic regions to infer chromosome copy number variation [87]. Similar examples include head and neck cancer [88] and human oligodendroglioma [89]. It is reported that RNA sequence of tumor-educated blood platelets (TEPs) can also become a blood-based cancer diagnosis method [90]. It should be noted that the lack of detailed functional implications of the identified RNAs in platelets in the field of platelet RNA research is also an urgent problem to be solved [91]. Cancer heterogeneity and evolution Heterogeneity has always existed during the transformation of normal cells to cancer cells. The continuous accumulation of heterogeneity may reflect the evolution of cancer [109]. Early RNA sequencing detected all RNA transcripts in a given tissue or cell group, ignoring differences in individual cells. Transcriptome profiling of single-cell RNA sequencing solves this problem by providing single-cell resolution of the transcriptome [3]. In melanoma, single-cell RNA-seq was used to analyze 4645 tumor cells from 19 patients, including cancer cells, immune cells, mesenchymal cells and endothelial cells. Transcriptomic data from different single cells revealed that heterogeneity of cells within the same cancer is associated with cell cycle, spatial background and drug resistance [110]. A recent single-cell RNA-seq study of 49 samples of metastatic lung cancer revealed changes in plasticity induced by non-small cell lung cancer treatment, providing new directions for clinical treatment [111]. Single-cell RNA sequencing also integrates a variety of information in a single cancer cell, deciphering the secrets of cancer heterogeneity and evolution [112]. Compared with scRNA-seq, another emerging technology spatial transcriptome sequencing incorporates information on the spatial location of cells. In prostate cancer, using spatial transcriptomics technology, the transcriptome of nearly 6750 tissue regions was analyzed, revealing the whole-tissue gene expression heterogeneity of the entire multifocal prostate cancer and accurately describing the range of cancer foci [113]. In a study of breast cancer tissues, the results of spatial transcriptome sequencing revealed that gene expression among different regions was surprisingly highly heterogeneous [22]. In recent years, single-nucleus RNA sequencing (snRNA-seq) has also received extensive attention due to its solving the problem that single-cell RNA sequencing cannot be applied to frozen specimens and cannot obtain all cell types in a given tissue [114, 115]. The emerging technology of RNA sequencing will contribute to research on cancer heterogeneity and evolution. Cancer drug resistance Drug resistance is a main reason leading to cancer treatment failure. However, the molecular mechanisms underlying drug resistance are still poorly understood [116]. RNA sequencing became a vital tool for revealing the mechanisms of cancer drug resistance. In breast cancer, single-cell RNA sequencing identified a tumor-infiltrating immunosuppressive immature myeloid cell that leads to drug resistance [117]. Another study identified a new COX7B gene related to platinum resistance and a surrogate marker CD63 in cancer cells by single-cell RNA-seq [118]. RNA sequencing has also demonstrated that cancer cells that wake up from a dormant state produce large amounts of BORIS (brother of the regulator of imprinted sites), which can regulate the expression of survival genes in drug-resistant neuroblastoma cells [119]. Identifying special molecules that mediate these processes could help us understand the occurrence of drug resistance. Single-cell transcriptomics can be used to study different modes of chemoresistance in tumor cells and has shown that pre-existing drug-resistant cells can be selected through higher phenotypic intratumoral heterogeneity, while phenotypic homogeneous cells use other mechanisms to trans-differentiate under drug-selection [120]. In one study of pancreatic ductal adenocarcinoma, human pancreatic cancer (PANC-1) cells and gemcitabine-resistant PANC-1 cell lines were compared by RNA sequencing, and two circRNAs were identified as both novel biomarkers and potential therapeutic targets for gemcitabine resistant patients [121]. RNA-seq has also conducted in-depth research on the drug resistance of hematological malignancies. Through RNA-seq, it has been found that non-coding RNAs and fusion genes play an important role in mediating the drug resistance of hematological malignancies [122]. A good example is to compare the circRNA expression profile of the drug-resistant acute myeloid leukemia cell with its parent cell, and determine the circRNAs involved in drug resistance [123]. Similarly, the novel MEF2D-BCL9 fusion transcript identified by RNA-seq was found to increase HDAC9 (histone deacetylase 9) expression and to enhance the resistance to dexamethasone in acute lymphocytic leukemia (ALL) [124]. Leukemia stem cells (LSCs), a rare cell population assumed to be responsible for relapse, is crucial to improve the prognosis of patients [125, 126]. RNA-seq analysis showed that LSCs have a unique lncRNA signature with functional relevance and therapeutic potential, providing an explanation for chemotherapy resistance and disease recurrence [127]. The cancer microenvironment and immunotherapy The immune system plays a critical role in the cancer microenvironment, affecting several stages of cancer development, including tumorigenesis, progression and metastasis, through tumor-infiltrating lymphocytes (TILs) [128]. TILs and their interactions with malignant cells and stromal cells make up the cancer immune microenvironment. Due to the heterogeneity of cancer, it is difficult to define the exact pro- or anti-cancer function of certain immune cells. Cancer heterogeneity also causes the varied clinical efficacy observed in patients treated with immunotherapies due to different responses of different subclones [129]. Transcriptomic profiling by RNA-seq, in particular scRNA-seq, provides comprehensive information on cellular activity and interactions among cells in the tumor microenvironment (TME). ScRNA-seq enables genomic and molecular profiling of high quantity and quality individual immune cells and assessment of cellular heterogeneity to depict the immune system spectrum in the cancer microenvironment [130–132]. ScRNA-seq data demonstrated that compared to normal tissues, cancer tissues exhibited significantly higher heterogeneity in the immune microenvironment, and a continuity in T cell activation resulting from polyclonal T cells and heterogeneous antigen-presenting cells has been identified [133]. ScRNA-seq of tumor-infiltrating T cells in metastatic melanoma identified transcription factor NFATC1 (nuclear factor of activated T cells 1) as a potential molecular signature of T cell exhaustion programs and revealed the depletion of low-exhaustion T cells in expanded clones of T cells [110]. Combining scRNA-seq with assembled T cell receptor (TCR) sequences, 11 T cell subsets, such as CD8 + T cells and CD8 + FOXP3 + regulatory-like cells, and their genomic signatures, were identified in hepatocellular carcinoma (HCC), providing valuable insights for understanding the immune landscape of infiltrating T cells in HCC [134]. Cancer infiltrating T cells also play an anti-tumor role through impairment of an autophagy protein, LC3 (microtubule-associated protein 1A/1B-light chain 3, often short for LC3)-associated phagocytosis (LAP), demonstrating the role of autophagy in oncogenesis and suppression revealed by scRNA-seq [135]. In addition to solid tumors, scRNA-seq of acute myeloid leukemia patients detected diverse immunomodulatory genes that suppress T cell function [136]. By CSOmap, a computational tool for scRNA-seq, the CCL4-CCR8 directed interaction between Tregs and Texs, as well as reduced proliferation of Texs, was characterized [137]. Notably, findings also revealed that tumor-infiltrating T cells exhibited more interactions among themselves than with T cells from peripheral blood and different interactions between tumors and T cells, indicating a varied response to immunotherapy and a potential trend for immune escape [137]. In the cancer immune microenvironment, neutrophils, in addition to T cells, are also key components of cancer progression and cancer drug resistance [138–141]. Through scRNA-seq of murine sarcomas and certain human cancers, neutrophils with CSF3R (colony stimulating factor 3 receptor) expression were found to be a part of type 1 antitumor immunity associated with unconventional CD4−CD8−αβ T cells (UTCαβ) in anti-cancer immunity, indicating better prognosis [142]. ScRNA-seq of metastatic breast cancer and CD45 cells from primary cancer identified neutrophils as pro- and anti-tumorigenic or metastatic, in which pro-tumorigenic and metastatic neutrophils are induced by IL11 expressing cancer subclones, resulting in polyclonal metastasis [143]. This observation also provides new insight into anti-cancer immunotherapy by targeting neutrophils [143]. With scRNA-seq of CD4 and CD8 T cells, several crucial pathways with anti-cancer function were revealed [144]. The balance between immune reaction and immune tolerance is the basis of immune homeostasis, which is also involved in anti-cancer immunity and oncogenesis. scRNA-seq of monocytes and dendritic cells (DCs) separated from a single lymph node melanoma metastasis revealed a conserved homeostatic module regulated by suppressor-of-cytokine-2 (SOCS2) protein and IFNγ [145]. SOCS2 serves an essential regulatory role in anti-tumor immunity and T cell priming through DCs. This highly conserved homeostatic program establishes a connection between autoimmune prevention and immune surveillance in cancer [145]. Immunotherapies, especially immune checkpoint blockade (ICB), has opened a new chapter for anti-cancer therapy with remarkable responses from targeting programmed death 1 (PD1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) [146–148]. However, only a few patients benefit from ICB, and severe side effects were observed [149, 150]. Obviously, various unknown determinants are correlated with the outcome of immunotherapies in addition to well-known factors such as PD1/PD-L1/CTLA-4 expression and mismatch repair deficiency [151–155]. Therefore, it is paramount to identify potential effectors for ICB efficacy. By analyzing RNA-seq data from melanoma patients who underwent anti-PD1 and anti-CTLA4 treatment, a potential ICB resistance effector SERPINB9 (a member of the serine protease inhibitor (serpin) family) and the connection between cytotoxic T lymphocytes (CTL) infiltration level and ICB response were characterized [156]. A sub-population cells with immunotherapy persistence have been identified by scRNA-seq and were found to have stem cell-like states with the expression of stem cell antigen-1 (Sca-1) and Snai1 [157]. Another immunotherapy, myeloid-targeted immunotherapy, is based on the complexity of tumor-infiltrating myeloid cells, including DCs and tumor-associated macrophages (TAMs) revealed by scRNA-seq [158]. Through scRNA-seq of immune cells from colorectal cancer patients, C1QC + and SPP1 + TAMs, two subsets of TAMs, were identified, and the mechanism of myeloid-targeted immunotherapy, such as anti-CSF1R (colony stimulating factor 1 receptor) and CD40 agonist, was revealed [159]. Intracellular staining and sequencing (INs-seq), a novel technology integrating scRNA-seq and intracellular protein activity measurements, revealed novel Arg1 + Trem2 + regulatory myeloid (Mreg) cells and demonstrated that depletion of Trem2 led to deduction of exhausted CD8 T cells with increased NK and cytotoxic T cells and cancer suppression by reducing accumulation of intratumoral Mreg cells [160]. Cancer neoantigens Neoantigens, human leukocyte antigen (HLA)-bound peptides derived from cancer-specific somatic mutations or gene fusions during tumor growth, are another crucial regulator of the clinical response to immunotherapy [161]. Higher intratumor neoantigen heterogeneity and clonal neoantigen burden increases sensitivity to ICB and contributes to better clinical outcome in patients with melanoma and advanced non-small cell lung cancer [162]. This kind of antigen is an optimal target for anti-cancer immunotherapy, enhancing neoantigen-specific T cell activity, and a vaccine targeting personal neoantigens for melanoma patients has been developed [163, 164]. Given all these promising features of personalized medicine targeting neoantigens in tumors, massive parallel profiling of tumor neoantigen burden is necessary for improving clinical efficacy and a deeper understanding of the neoantigen landscape. An RNA-seq-based transcriptomic approach is an efficient tool for neoantigen profiling in many studies. It was revealed that homology of neoantigen and somatic-mutation induced pathogens are important in response prediction in anti-CTLA4 treated melanoma [165]. In addition to melanoma, other studies found reduced neoantigen load in triple-negative and HER2 breast cancers [166], diverse neoantigen abundance in non-small-cell lung cancer patients with different treatment strategies [167], a decreased ratio of neoantigen expression to predicted neoantigens in recurrent glioma due to immune selection pressure [168], a negative correlation between neoantigen abundance and clinical outcome in selected solid tumors [169] and different neoantigen landscapes in immune filtration and T cell dysfunction based on histology in salivary gland carcinoma (SGC) patients [170]. A neoantigen prediction program, Neopepsee, based on RNA-seq data and somatic mutation, can be utilized to detect potential neoantigens for personal vaccine development with reduced false-positive rate compared to binding affinity prediction [171]. ScanNeo is another prediction computational pipeline based on RNA-seq that aims to identify insertion and deletion derived neoantigens, which was validated in prostate cancer [172], and ASNEO, which identifies personal-specific alternative splicing derived neoantigens [173]. Several neoantigens have been identified to be related to cancer prognosis and might be potential targets of immunotherapies, such as the TP53 neoantigen for HCC patients [174]. For the anti-neoantigen immunotherapy in cancer, a new strategy involving neoantigen-specific TCRs modification has been proposed, and scRNA-seq has been applied to isolate neoantigen-specific TCRs for further clinical application [175]. Conclusions and perspectives High-throughput RNA-seq technology has been a major tool to explore the transcriptome. The rapid development of RNA-seq technology not only saves time and cost but also sheds light on many new research fields. However, there are still limitations of RNA-seq technology that need to be improved. For short-read length RNA-seq technologies, bias and imperfections are primarily generated in sequencing library preparation and short read assembly. It is difficult for these methods to correctly identify multiple isoforms from a certain gene. To overcome the disadvantage of short read length, improved read coverage and sequencing depth is required. Long-read length RNA-seq technologies avoid shortcomings in template amplification, reduce the false positive rate in splice junction detection and enable the identification of unannotated longer transcripts, overcoming the common limitations of short-read sequencing [176, 177]. However, this method suffers from the drawback of reduced throughput, higher cost and higher sequencing error rate, especially insertion-deletion errors. To reduce random errors, PacBio circular consensus-sequencing (CCS) was developed to increase sequencing depth by rereading molecules several times. However, it also reduces the identification rate of unique isoforms. In addition, the sensitivity of long-read sequencing for identification of differentially expressed genes is lower compared to short-read sequencing [178–180]. Thus, hybridization of long-read and short-read sequencing has been reported to yield a more comprehensive and accurate analysis [181]. Improvements in the throughput of RNA sequencing technology have resulted in billions of sequencing reads, bringing great challenges to the computational process, such as data storage, transmission, quality control and data analysis, including read mapping, transcript assembly and read normalization. Therefore, it is important for bioinformatics to keep pace with the continuous developments of RNA-seq technologies. Notably, bias could be produced due to differences in read data handling, necessitating the improvement of current bioinformatics pipelines. RNA-seq measures gene expression by the read counts, which always containing missing values, thus results in information loss of specific gene and negative impact on downstream analysis. To overcome this problem, missing data need to be imputed and analyzed by several methods, such as optimal clustering with missing values [182]. For scRNA-seq, the proportion of genes with zero or low expression varies across cells due to biological or technical bias. For example, batch effects can come from cells captured and sequenced in different conditions [183]. Imputation methods, such as SAVER, MAGIC and kNN-smoothing, are recommended for scRNA-seq [184]. Another method named batch effects correction with unknown subtypes for scRNA-seq data (BUSseq) utilizes Bayesian hierarchical model and can also be used to correct batch effects and missing data [185]. Combination of data from multi-omics sequencing can undoubtedly expand the application of RNA-seq. For example, Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) was developed by utilizing hyperactive Tn5 transposase to identify open chromatin region and transcriptional factor (TF) binding sites [186]. The integration of ATAC-seq and RNA-seq enables the reveal of TF-targeted genes and their transcripts [187, 188]. Chromatin conformation capture analysis (3C) technology and its several derivatives including circular chromosome conformation capture (4C), carbon copy chromosome conformation capture (5C), ChIP-Loop, Hi-C and capture Hi-C were developed and improved to detect chromatin structure as well as unknown interacting regions [189–191]. It has been reported that combined analysis of RNA-seq and chromatin structure can detect structure variation-related differentially expressed genes [192–194]. Epitranscriptomics is a crucial part of gene expression, and methylation of adenosine at the N6 position (m6A) is the most abundant [195]. Traditional RNA-seq needs reverse transcription before sequencing and thus easily loses the information of transcriptome complexity. This shortcoming can be overcome by directly sequencing native RNA molecules using methods such as nanopore sequencing. Transcript modifications could be inferred from the current signal as the modified RNA molecules passing nanopore cause a characteristic temporary current blockade, which enables the detection of diverse modifications such as m6A or 5-methylcytosine (m5C) [196–198]. ScRNA-seq is a powerful technology to facilitate further exploration in cancer research and also has been employed in the detection of cancer stem cell subpopulation, metabolic switch in cancer-draining lymph nodes and therapy-induced adaption of cancer cells [111, 199, 200]. Combined with cell sorting or ligand-receptor interaction, scRNA-seq was utilized in cellular interaction, cell spatial organization as well as molecular crosstalk characterization [137, 201, 202]. Coupling of parallel CRISPR (clustered regularly interspaced short palindromic repeats)-pooled screen, scRNA-seq enables the simultaneous analysis of genomic perturbation and transcriptional activity to detect heterogeneous cell type as well as crucial factors of complexity regulatory mechanism [203–205]. ScNT-seq, single-cell metabolically labeled new RNA tagging sequencing, brings RNA-seq into time resolution by identifying RNAs transcribed at different stage [206]. Utilizing SNP-based demultiplexing of scRNA-seq data, MIX-Seq was developed to study cancer cell reaction to pharmacologic treatment [207]. Another technology, snRNA-seq, is invaluable for detecting cellular heterogeneity of cancer and has been employed to identification of a sub-population of adipocytes regulating cancer genesis [208]. Taken together, RNA-seq has been applied in an impressively wide range of cancer research. All applications in cancer research rely on the boost of advanced RNA-seq technologies, especially the combination of scRNA-seq and spatial transcriptomics as well as data from multi-omics, which will bring RNA-seq technologies into single-cell resolution and tissue-level transcriptomics, providing new insight into cancer diagnosis, treatment and prevention. Abbreviations RNA-seqRNA sequencing ScRNA-seqSingle-cell RNA sequencing SOLiDSequencing by Oligonucleotide Ligation and Detection DNBSDNA nanoball sequencing NGSNext-generation sequencing PacBio SMRTPacific Biosciences single-molecule real-time ONTOxford Nanopore Technologies Sci-RNA-seqSingle-cell combinatorial indexing RNA sequencing SPLiT-seqSplit-pool ligation-based transcriptome sequencing LCMLaser capture microdissection FISSEQFluorescent in situ RNA sequencing RCARolling-circle amplification AMLAcute myeloid leukemia SSRsSimple repetitive sequences COX2Cyclooxygenase2 HER2Human epidermal growth factor receptor type 2 ISG15Interferon-stimulated gene 15 DMGDHDimethylglycine dehydrogenase TMBTumor mutation burden IDHIsocitrate dehydrogenase CNVCopy number variations TEPsTumor-educated blood platelets SnRNA-seqSingle-nucleus RNA-sequencing BORISBrother of the regulator of imprinted sites ALLAcute lymphocytic leukemia LSCsLeukemia stem cells TILsTumor-infiltrating lymphocytes TMETumor microenvironment NFATC1Nuclear factor of activated T cells 1 TCRT cell receptor HCCHepatocellular carcinoma LAPMicrotubule-associated protein 1A/1B-light chain 3-associated phagocytosis CSF3RColony stimulating factor 3 receptor UTCαβUnconventional CD4−CD8− αβ T cells DCsDendritic cells SOCS2Suppressor-of-cytokine-2 protein ICBImmune checkpoint blockade PD1Targeting programmed death 1 PD-L1Programmed death-ligand 1 CTLA4Cytotoxic T-lymphocyte-associated protein 4 CTLCytotoxic T lymphocytes Sca-1Stem cell antigen-1 TAMsTumor-associated macrophages CSF1RColony stimulating factor 1 receptor INs-seqIntracellular staining and sequencing MregRegulatory myeloid cells HLAHuman leukocyte antigen SGCSalivary gland carcinoma CCSCircular consensus-sequencing ATAC-seqAssay for Transposase-Accessible Chromatin using sequencing TFTranscriptional factor 3CChromatin conformation capture analysis 4CCircular chromosome conformation capture 5CCarbon copy chromosome conformation capture m6AN6 position m5C5-Methylcytosine CRISPRClustered regularly interspaced short palindromic repeats Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Mingye Hong and Shuang Tao have contributed equally to this work Acknowledgements Not applicable. Authors’ contributions M.H. and S.T. wrote and edited this manuscript and created figures and tables. L.Z., L-T. D., X-M. H., S-H. H., S-J. X., Z-D. X and H.Z. reviewed and revised the manuscript. Z-D. X and H.Z. provided direction and guidance throughout the preparation of the manuscript. All authors read and approved the final manuscript. Funding This work was supported by the National Natural Science Foundation of China (81300398 and 81974436); Key-Area Research and Development Program of Guangdong Province (2020B1111030005); The Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2019ZT08Y485); Key Program of Marine Economy Development (Six Marine Industries) Special Foundation of Department of Natural Resources of Guangdong Province (GDNRC [2020]070); The Fundamental Research Funds for the Central Universities (19ykzd06) and the Opening Fund of Guangdong Key Laboratory of Marine Materia Medica (LMM2020-4). Availability of data and materials Not applicable. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. ==== Refs References 1. Margulies M Egholm M Altman WE Attiya S Bader JS Bemben LA Genome sequencing in microfabricated high-density picolitre reactors Nature 2005 437 376 380 10.1038/nature03959 16056220 2. Cieślik M Chinnaiyan AM Cancer transcriptome profiling at the juncture of clinical translation Nat Rev Genet 2018 19 93 109 10.1038/nrg.2017.96 29279605 3. Suvà ML Tirosh I Single-cell RNA sequencing in cancer: lessons learned and emerging challenges Mol Cell 2019 75 7 12 10.1016/j.molcel.2019.05.003 31299208 4. Watson JD Crick FH Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid Nature 1953 171 737 738 10.1038/171737a0 13054692 5. Sanger F Nicklen S Coulson AR DNA sequencing with chain-terminating inhibitors Proc Natl Acad Sci USA 1977 74 5463 5467 10.1073/pnas.74.12.5463 271968 6. Maxam AM Gilbert W A new method for sequencing DNA Proc Natl Acad Sci USA 1977 74 560 564 10.1073/pnas.74.2.560 265521 7. Sanger F Air GM Barrell BG Brown NL Coulson AR Fiddes CA Nucleotide sequence of bacteriophage phi X174 DNA Nature 1977 265 687 695 10.1038/265687a0 870828 8. Russo G Zegar C Giordano A Advantages and limitations of microarray technology in human cancer Oncogene 2003 22 6497 6507 10.1038/sj.onc.1206865 14528274 9. Li S Tighe S Nicolet C Grove D Levy S Farmerie W Multi-platform assessment of transcriptome profiling using RNA-seq in the ABRF next-generation sequencing study Nat Biotechnol 2014 32 915 925 10.1038/nbt.2972 25150835 10. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium. Nat Biotechnol. 2014;32:903–14. 11. Mardis E Next-generation DNA sequencing methods Annu Rev Genomics Hum Genet 2008 9 387 402 10.1146/annurev.genom.9.081307.164359 18576944 12. Shendure J Ji H Next-generation DNA sequencing Nat Biotechnol 2008 26 1135 1145 10.1038/nbt1486 18846087 13. Mardis E Next-generation sequencing platforms Annu Rev Anal Chem (Palo Alto Calif) 2013 6 287 303 10.1146/annurev-anchem-062012-092628 23560931 14. Marioni JC Mason CE Mane SM Stephens M Gilad Y RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays Genome Res 2008 18 1509 1517 10.1101/gr.079558.108 18550803 15. Schadt EE Turner S Kasarskis A A window into third-generation sequencing Hum Mol Genet 2010 19 R227 R240 10.1093/hmg/ddq416 20858600 16. Eid J Fehr A Gray J Luong K Lyle J Otto G Real-time DNA sequencing from single polymerase molecules Science 2009 323 133 138 10.1126/science.1162986 19023044 17. Hart C Lipson D Ozsolak F Raz T Steinmann K Thompson J Single-molecule sequencing: sequence methods to enable accurate quantitation Methods Enzymol 2010 472 407 430 10.1016/S0076-6879(10)72002-4 20580974 18. Bayley H Nanopore sequencing: from imagination to reality Clin Chem 2015 61 25 31 10.1373/clinchem.2014.223016 25477535 19. Tang F Barbacioru C Wang Y Nordman E Lee C Xu N mRNA-Seq whole-transcriptome analysis of a single cell Nat Methods 2009 6 377 382 10.1038/nmeth.1315 19349980 20. Cao J Packer J Ramani V Cusanovich D Huynh C Daza R Comprehensive single-cell transcriptional profiling of a multicellular organism Science 2017 357 661 667 10.1126/science.aam8940 28818938 21. Rosenberg A Roco C Muscat R Kuchina A Sample P Yao Z Single-cell profiling of the developing mouse brain and spinal cord with split-pool barcoding Science 2018 360 176 182 10.1126/science.aam8999 29545511 22. Ståhl P Salmén F Vickovic S Lundmark A Navarro J Magnusson J Visualization and analysis of gene expression in tissue sections by spatial transcriptomics Science 2016 353 78 82 10.1126/science.aaf2403 27365449 23. Rodriques SG Stickels RR Goeva A Martin CA Murray E Vanderburg CR Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution Science 2019 363 1463 1467 10.1126/science.aaw1219 30923225 24. Chen J Suo S Tam PP Han JJ Peng G Jing N Spatial transcriptomic analysis of cryosectioned tissue samples with geo-seq Nat Protoc 2017 12 566 580 10.1038/nprot.2017.003 28207000 25. Ke R Mignardi M Pacureanu A Svedlund J Botling J Wählby C In situ sequencing for RNA analysis in preserved tissue and cells Nat Methods 2013 10 857 860 10.1038/nmeth.2563 23852452 26. Lee JH Daugharthy ER Scheiman J Kalhor R Yang JL Ferrante TC Highly multiplexed subcellular RNA sequencing in situ Science 2014 343 1360 1363 10.1126/science.1250212 24578530 27. Mercer TR Gerhardt DJ Dinger ME Crawford J Trapnell C Jeddeloh JA Targeted RNA sequencing reveals the deep complexity of the human transcriptome Nat Biotechnol 2011 30 99 104 10.1038/nbt.2024 22081020 28. Heyer EE Deveson IW Wooi D Selinger CI Lyons RJ Hayes VM Diagnosis of fusion genes using targeted RNA sequencing Nat Commun 2019 10 1388 10.1038/s41467-019-09374-9 30918253 29. Soverini S Abruzzese E Bocchia M Bonifacio M Galimberti S Gozzini A Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper J Hematol Oncol 2019 12 131 10.1186/s13045-019-0815-5 31801582 30. Chatterjee A Ahn A Rodger EJ Stockwell PA Eccles MR A guide for designing and analyzing RNA-seq data Methods Mol Biol 2018 1783 35 80 10.1007/978-1-4939-7834-2_3 29767357 31. Conesa A Madrigal P Tarazona S Gomez-Cabrero D Cervera A McPherson A A survey of best practices for RNA-seq data analysis Genome Biol 2016 17 13 10.1186/s13059-016-0881-8 26813401 32. Cock PJ Fields CJ Goto N Heuer ML Rice PM The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants Nucleic Acids Res 2010 38 1767 1771 10.1093/nar/gkp1137 20015970 33. Chen S Zhou Y Chen Y Gu J fastp: an ultra-fast all-in-one FASTQ preprocessor Bioinformatics 2018 34 i884 i890 10.1093/bioinformatics/bty560 30423086 34. Patel RK Jain M NGS QC Toolkit: a toolkit for quality control of next generation sequencing data PLoS ONE 2012 7 e30619 10.1371/journal.pone.0030619 22312429 35. DeLuca DS Levin JZ Sivachenko A Fennell T Nazaire MD Williams C RNA-SeQC: RNA-seq metrics for quality control and process optimization Bioinformatics 2012 28 1530 1532 10.1093/bioinformatics/bts196 22539670 36. Bolger AM Lohse M Usadel B Trimmomatic: a flexible trimmer for Illumina sequence data Bioinformatics 2014 30 2114 2120 10.1093/bioinformatics/btu170 24695404 37. Schmieder R Edwards R Quality control and preprocessing of metagenomic datasets Bioinformatics 2011 27 863 864 10.1093/bioinformatics/btr026 21278185 38. Chen Y Chen Y Shi C Huang Z Zhang Y Li S SOAPnuke: a MapReduce acceleration-supported software for integrated quality control and preprocessing of high-throughput sequencing data Gigascience 2018 7 1 6 29659813 39. Kim D Pertea G Trapnell C Pimentel H Kelley R Salzberg SL TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions Genome Biol 2013 14 R36 10.1186/gb-2013-14-4-r36 23618408 40. Kim D Langmead B Salzberg SL HISAT: a fast spliced aligner with low memory requirements Nat Methods 2015 12 357 360 10.1038/nmeth.3317 25751142 41. Dobin A Davis CA Schlesinger F Drenkow J Zaleski C Jha S STAR: ultrafast universal RNA-seq aligner Bioinformatics 2013 29 15 21 10.1093/bioinformatics/bts635 23104886 42. Li H Durbin R Fast and accurate short read alignment with Burrows–Wheeler transform Bioinformatics 2009 25 1754 1760 10.1093/bioinformatics/btp324 19451168 43. Langmead B Trapnell C Pop M Salzberg SL Ultrafast and memory-efficient alignment of short DNA sequences to the human genome Genome Biol 2009 10 R25 10.1186/gb-2009-10-3-r25 19261174 44. Trapnell C Williams BA Pertea G Mortazavi A Kwan G van Baren MJ Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation Nat Biotechnol 2010 28 511 515 10.1038/nbt.1621 20436464 45. Pertea M Pertea GM Antonescu CM Chang TC Mendell JT Salzberg SL StringTie enables improved reconstruction of a transcriptome from RNA-seq reads Nat Biotechnol 2015 33 290 295 10.1038/nbt.3122 25690850 46. Grabherr MG Haas BJ Yassour M Levin JZ Thompson DA Amit I Full-length transcriptome assembly from RNA-Seq data without a reference genome Nat Biotechnol 2011 29 644 652 10.1038/nbt.1883 21572440 47. Hurgobin B Short read alignment using SOAP2 Methods Mol Biol 2016 1374 241 252 10.1007/978-1-4939-3167-5_13 26519410 48. Robertson G Schein J Chiu R Corbett R Field M Jackman SD De novo assembly and analysis of RNA-seq data Nat Methods 2010 7 909 912 10.1038/nmeth.1517 20935650 49. Liao Y Smyth GK Shi W featureCounts: an efficient general purpose program for assigning sequence reads to genomic features Bioinformatics 2014 30 923 930 10.1093/bioinformatics/btt656 24227677 50. Anders S Pyl PT Huber W HTSeq: a python framework to work with high-throughput sequencing data Bioinformatics 2015 31 166 169 10.1093/bioinformatics/btu638 25260700 51. Roberts A Pachter L Streaming fragment assignment for real-time analysis of sequencing experiments Nat Methods 2013 10 71 73 10.1038/nmeth.2251 23160280 52. Li B Dewey CN RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome BMC Bioinform 2011 12 323 10.1186/1471-2105-12-323 53. Anders S Reyes A Huber W Detecting differential usage of exons from RNA-seq data Genome Res 2012 22 2008 2017 10.1101/gr.133744.111 22722343 54. Bray NL Pimentel H Melsted P Pachter L Near-optimal probabilistic RNA-seq quantification Nat Biotechnol 2016 34 525 527 10.1038/nbt.3519 27043002 55. Patro R Mount SM Kingsford C Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms Nat Biotechnol 2014 32 462 464 10.1038/nbt.2862 24752080 56. Patro R Duggal G Love MI Irizarry RA Kingsford C Salmon provides fast and bias-aware quantification of transcript expression Nat Methods 2017 14 417 419 10.1038/nmeth.4197 28263959 57. Love MI Huber W Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 Genome Biol 2014 15 550 10.1186/s13059-014-0550-8 25516281 58. Robinson MD McCarthy DJ Smyth GK edgeR: a Bioconductor package for differential expression analysis of digital gene expression data Bioinformatics 2010 26 139 140 10.1093/bioinformatics/btp616 19910308 59. Moon M Nakai K Stable feature selection based on the ensemble L (1)-norm support vector machine for biomarker discovery BMC Genomics 2016 17 1026 10.1186/s12864-016-3320-z 28155664 60. Zubovic L Piazza S Tebaldi T Cozzuto L Palazzo G Sidarovich V The altered transcriptome of pediatric myelodysplastic syndrome revealed by RNA sequencing J Hematol Oncol 2020 13 135 10.1186/s13045-020-00974-3 33046098 61. Oshlack A Robinson MD Young MD From RNA-seq reads to differential expression results Genome Biol 2010 11 220 10.1186/gb-2010-11-12-220 21176179 62. Govindarajan M Wohlmuth C Waas M Bernardini MQ Kislinger T High-throughput approaches for precision medicine in high-grade serous ovarian cancer J Hematol Oncol 2020 13 134 10.1186/s13045-020-00971-6 33036656 63. Wu H Li X Li H Gene fusions and chimeric RNAs, and their implications in cancer Genes Dis 2019 6 385 390 10.1016/j.gendis.2019.08.002 31832518 64. Reeser JW Martin D Miya J Kautto EA Lyon E Zhu E Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors J Mol Diagn 2017 19 682 696 10.1016/j.jmoldx.2017.05.006 28802831 65. Mercer TR Clark MB Crawford J Brunck ME Gerhardt DJ Taft RJ Targeted sequencing for gene discovery and quantification using RNA CaptureSeq Nat Protoc. 2014 9 989 1009 10.1038/nprot.2014.058 24705597 66. Togni M Masetti R Pigazzi M Astolfi A Zama D Indio V Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing J Hematol Oncol 2015 8 69 10.1186/s13045-015-0167-8 26066811 67. Veeraraghavan J Ma J Hu Y Wang XS Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications Breast Cancer Res Treat 2016 158 219 232 10.1007/s10549-016-3876-y 27372070 68. Kloosterman WP, Coebergh van den Braak RRJ, Pieterse M, van Roosmalen MJ, Sieuwerts AM, Stangl C, et al. A systematic analysis of oncogenic gene fusions in primary colon cancer. Cancer Res. 2017;77:3814–22. 69. Sun YM Chen YQ Principles and innovative technologies for decrypting noncoding RNAs: from discovery and functional prediction to clinical application J Hematol Oncol 2020 13 109 10.1186/s13045-020-00945-8 32778133 70. Zhou X Zhan L Huang K Wang X The functions and clinical significance of circRNAs in hematological malignancies J Hematol Oncol 2020 13 138 10.1186/s13045-020-00976-1 33069241 71. Liu Y Cheng Z Pang Y Cui L Qian T Quan L Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia J Hematol Oncol 2019 12 51 10.1186/s13045-019-0734-5 31126316 72. Xu H Wang C Song H Xu Y Ji G RNA-Seq profiling of circular RNAs in human colorectal Cancer liver metastasis and the potential biomarkers Mol Cancer 2019 18 8 10.1186/s12943-018-0932-8 30630466 73. Alisoltani A Fallahi H Shiran B Alisoltani A Ebrahimie E RNA-seq SSRs and small RNA-seq SSRs: new approaches in cancer biomarker discovery Gene 2015 560 34 43 10.1016/j.gene.2015.01.027 25639356 74. Zhou FF Huang R Jiang J Zeng XH Zou SQ Correlated non-nuclear COX2 and low HER2 expression confers a good prognosis in colorectal cancer Saudi J Gastroenterol 2018 24 301 306 10.4103/sjg.SJG_46_18 29873317 75. Chen RH Du Y Han P Wang HB Liang FY Feng GK ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma Oncotarget 2016 7 16910 16922 10.18632/oncotarget.7626 26919245 76. Liu G Hou G Li L Li Y Zhou W Liu L Potential diagnostic and prognostic marker dimethylglycine dehydrogenase (DMGDH) suppresses hepatocellular carcinoma metastasis in vitro and in vivo Oncotarget 2016 7 32607 32616 10.18632/oncotarget.8927 27119355 77. Mei J Hao L Liu X Sun G Xu R Wang H Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer Biomark Res 2019 7 16 10.1186/s40364-019-0168-9 31402980 78. Wang L Ge J Lan Y Shi Y Luo Y Tan Y Tumor mutational burden is associated with poor outcomes in diffuse glioma BMC Cancer 2020 20 213 10.1186/s12885-020-6658-1 32164609 79. Jiang T Shi J Dong Z Hou L Zhao C Li X Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma J Hematol Oncol 2019 12 75 10.1186/s13045-019-0762-1 31299995 80. Seo JS Ju YS Lee WC Shin JY Lee JK Bleazard T The transcriptional landscape and mutational profile of lung adenocarcinoma Genome Res. 2012 22 2109 2119 10.1101/gr.145144.112 22975805 81. Nakagawa M Nakatani F Matsunaga H Seki T Endo M Ogawara Y Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma Oncogene. 2019 38 6835 49 10.1038/s41388-019-0929-9 31406254 82. Davies KD Lomboy A Lawrence CA Yourshaw M Bocsi GT Camidge DR DNA-based versus RNA-based detection of MET Exon 14 skipping events in lung cancer J Thorac Oncol 2019 14 737 741 10.1016/j.jtho.2018.12.020 30639620 83. Unruh D Zewde M Buss A Drumm MR Tran AN Scholtens DM Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers Sci Rep. 2019 9 8946 10.1038/s41598-019-45346-1 31222125 84. Yu J Jiang PYZ Sun H Zhang X Jiang Z Li Y Advances in targeted therapy for acute myeloid leukemia Biomark Res 2020 8 17 10.1186/s40364-020-00196-2 32477567 85. Yang X Wang J Precision therapy for acute myeloid leukemia J Hematol Oncol 2018 11 3 10.1186/s13045-017-0543-7 29301553 86. Gu R Yang X Wei H Molecular landscape and targeted therapy of acute myeloid leukemia Biomark Res 2018 6 32 10.1186/s40364-018-0146-7 30455953 87. Patel AP Tirosh I Trombetta JJ Shalek AK Gillespie SM Wakimoto H Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma Science 2014 344 1396 1401 10.1126/science.1254257 24925914 88. Puram SV Tirosh I Parikh AS Patel AP Yizhak K Gillespie S Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer Cell 2017 171 1611–24 e24 89. Tirosh I Venteicher AS Hebert C Escalante LE Patel AP Yizhak K Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma Nature 2016 539 309 313 10.1038/nature20123 27806376 90. Best MG Sol N Kooi I Tannous J Westerman BA Rustenburg F RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics Cancer Cell 2015 28 666 676 10.1016/j.ccell.2015.09.018 26525104 91. Best MG Vancura A Wurdinger T Platelet RNA as a circulating biomarker trove for cancer diagnostics J Thromb Haemost 2017 15 1295 1306 10.1111/jth.13720 28671345 92. Zhu L Li J Gong Y Wu Q Tan S Sun D Exosomal tRNA-derived small RNA as a promising biomarker for cancer diagnosis Mol Cancer 2019 18 74 10.1186/s12943-019-1000-8 30940133 93. Nie Y Jiao Y Li Y Li W Investigation of the clinical significance and prognostic value of the lncRNA ACVR2B-As1 in liver cancer Biomed Res Int 2019 2019 4602371 31886217 94. Gong W, Yang L, Wang Y, Xian J, Qiu F, Liu L, et al. Analysis of survival-related lncRNA landscape identifies a role for LINC01537 in energy metabolism and lung cancer progression. Int J Mol Sci. 2019;20. 95. Hang D Zhou J Qin N Zhou W Ma H Jin G A novel plasma circular RNA circFARSA is a potential biomarker for non-small cell lung cancer Cancer Med 2018 7 2783 2791 10.1002/cam4.1514 29722168 96. Hua Q Jin M Mi B Xu F Li T Zhao L LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis J Hematol Oncol 2019 12 91 10.1186/s13045-019-0773-y 31488218 97. Wang Z, Qin B. Prognostic and clinicopathological significance of long noncoding RNA CTD-2510F5.4 in gastric cancer. Gastric Cancer. 2019;22:692–704. 98. Luo T Zhao J Lu Z Bi J Pang T Cui H Characterization of long non-coding RNAs and MEF2C-AS1 identified as a novel biomarker in diffuse gastric cancer Transl Oncol 2018 11 1080 1089 10.1016/j.tranon.2018.06.007 30005210 99. Wang D Wan X Zhang Y Kong Z Lu Y Sun X A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway Prostate 2019 79 1362 1377 31269242 100. Silva-Fisher JM Dang HX White NM Strand MS Krasnick BA Rozycki EB Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression Nat Commun 2020 11 2156 10.1038/s41467-020-15547-8 32358485 101. Yamada A Yu P Lin W Okugawa Y Boland CR Goel A A RNA-Sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer Sci Rep 2018 8 575 10.1038/s41598-017-18407-6 29330370 102. Bo H Fan L Li J Liu Z Zhang S Shi L High Expression of lncRNA AFAP1-AS1 Promotes the Progression of Colon Cancer and Predicts Poor Prognosis J Cancer 2018 9 4677 4683 10.7150/jca.26461 30588252 103. Chen Q Hu L Chen K Construction of a nomogram based on a hypoxia-related lncRNA signature to improve the prediction of gastric cancer prognosis Front Genet 2020 11 570325 10.3389/fgene.2020.570325 33193668 104. Guo YZ Sun HH Wang XT Wang MT Transcriptomic analysis reveals key lncRNAs associated with ribosomal biogenesis and epidermis differentiation in head and neck squamous cell carcinoma J Zhejiang Univ Sci B 2018 19 674 688 10.1631/jzus.B1700319 30178634 105. Yao Y Chen X Lu S Zhou C Xu G Yan Z Circulating long noncoding RNAs as biomarkers for predicting head and neck squamous cell carcinoma Cell Physiol Biochem 2018 50 1429 1440 10.1159/000494605 30355951 106. Gong X Siprashvili Z Eminaga O Shen Z Sato Y Kume H Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer Oncotarget 2017 8 18657 18669 10.18632/oncotarget.15703 28423633 107. James AR Schroeder MP Neumann M Bastian L Eckert C Gökbuget N Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia J Hematol Oncol 2019 12 8 10.1186/s13045-018-0692-3 30642353 108. Li S Ma Y Tan Y Ma X Zhao M Chen B Profiling and functional analysis of circular RNAs in acute promyelocytic leukemia and their dynamic regulation during all-trans retinoic acid treatment Cell Death Dis 2018 9 651 10.1038/s41419-018-0699-2 29844435 109. Guo M Peng Y Gao A Du C Herman JG Epigenetic heterogeneity in cancer Biomark Res 2019 7 23 10.1186/s40364-019-0174-y 31695915 110. Tirosh I Izar B Prakadan SM Wadsworth MH 2nd Treacy D Trombetta JJ Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq Science 2016 352 189 196 10.1126/science.aad0501 27124452 111. Maynard A McCoach CE Rotow JK Harris L Haderk F Kerr DL Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing Cell 2020 182 1232–51 e22 112. Nam AS, Chaligne R, Landau DA. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nat Rev Genet. 2020. 113. Berglund E Maaskola J Schultz N Friedrich S Marklund M Bergenstråhle J Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity Nat Commun 2018 9 2419 10.1038/s41467-018-04724-5 29925878 114. Bakken TE Hodge RD Miller JA Yao Z Nguyen TN Aevermann B Single-nucleus and single-cell transcriptomes compared in matched cortical cell types PLoS ONE 2018 13 e0209648 10.1371/journal.pone.0209648 30586455 115. Selewa A Dohn R Eckart H Lozano S Xie B Gauchat E Systematic comparison of high-throughput single-cell and single-nucleus transcriptomes during cardiomyocyte differentiation Sci Rep 2020 10 1535 10.1038/s41598-020-58327-6 32001747 116. Lim ZF Ma PC Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy J Hematol Oncol 2019 12 134 10.1186/s13045-019-0818-2 31815659 117. Wang Q Guldner IH Golomb SM Sun L Harris JA Lu X Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer Nat Commun 2019 10 3817 10.1038/s41467-019-11729-1 31444334 118. Tanaka N Katayama S Reddy A Nishimura K Niwa N Hongo H Single-cell RNA-seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63 Cancer Med 2018 7 6193 6204 10.1002/cam4.1828 30367559 119. Debruyne DN Dries R Sengupta S Seruggia D Gao Y Sharma B BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells Nature 2019 572 676 680 10.1038/s41586-019-1472-0 31391581 120. Sharma A Cao EY Kumar V Zhang X Leong HS Wong AML Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy Nat Commun 2018 9 4931 10.1038/s41467-018-07261-3 30467425 121. Shao F Huang M Meng F Huang Q Circular RNA SIgnature predicts gemcitabine resistance of pancreatic ductal adenocarcinoma Front Pharmacol 2018 9 584 10.3389/fphar.2018.00584 29922161 122. Wang WT Han C Sun YM Chen TQ Chen YQ Noncoding RNAs in cancer therapy resistance and targeted drug development J Hematol Oncol 2019 12 55 10.1186/s13045-019-0748-z 31174564 123. Shang J Chen WM Liu S Wang ZH Wei TN Chen ZZ CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy Leuk Res 2019 85 106198 10.1016/j.leukres.2019.106198 31401408 124. Suzuki K Okuno Y Kawashima N Muramatsu H Okuno T Wang X MEF2D-BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents J Clin Oncol 2016 34 3451 3459 10.1200/JCO.2016.66.5547 27507882 125. Pallarès V Unzueta U Falgàs A Sánchez-García L Serna N Gallardo A An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination J Hematol Oncol 2020 13 36 10.1186/s13045-020-00863-9 32295630 126. Ding Y Gao H Zhang Y Li Y Vasdev N Gao Y Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells J Hematol Oncol 2016 9 93 10.1186/s13045-016-0327-5 27658462 127. Bill M Papaioannou D Karunasiri M Kohlschmidt J Pepe F Walker CJ Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells Leukemia 2019 33 2169 2182 10.1038/s41375-019-0429-5 30858548 128. Fan X Rudensky AY Hallmarks of tissue-resident lymphocytes Cell 2016 164 1198 1211 10.1016/j.cell.2016.02.048 26967286 129. Burrell RA Swanton C Re-evaluating clonal dominance in cancer evolution Trends Cancer 2016 2 263 276 10.1016/j.trecan.2016.04.002 28741512 130. Shalek AK Satija R Adiconis X Gertner RS Gaublomme JT Raychowdhury R Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells Nature 2013 498 236 240 10.1038/nature12172 23685454 131. Pan Y Lu F Fei Q Yu X Xiong P Yu X Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer J Hematol Oncol 2019 12 124 10.1186/s13045-019-0822-6 31771616 132. Macosko EZ Basu A Satija R Nemesh J Shekhar K Goldman M Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets Cell 2015 161 1202 1214 10.1016/j.cell.2015.05.002 26000488 133. Azizi E Carr AJ Plitas G Cornish AE Konopacki C Prabhakaran S Single-cell map of diverse immune phenotypes in the breast tumor microenvironment Cell 2018 174 1293 1308 10.1016/j.cell.2018.05.060 29961579 134. Zheng C Zheng L Yoo JK Guo H Zhang Y Guo X Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing Cell 2017 169 1342 1356 10.1016/j.cell.2017.05.035 28622514 135. Cunha LD Yang M Carter R Guy C Harris L Crawford JC LC3-associated phagocytosis in myeloid cells promotes tumor immune tolerance Cell 2018 175 429 441 10.1016/j.cell.2018.08.061 30245008 136. van Galen P Hovestadt V Wadsworth Ii MH Hughes TK Griffin GK Battaglia S Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity Cell 2019 176 1265 1281 10.1016/j.cell.2019.01.031 30827681 137. Ren X Zhong G Zhang Q Zhang L Sun Y Zhang Z Reconstruction of cell spatial organization from single-cell RNA sequencing data based on ligand-receptor mediated self-assembly Cell Res 2020 30 763 778 10.1038/s41422-020-0353-2 32541867 138. Wculek SK Malanchi I Neutrophils support lung colonization of metastasis-initiating breast cancer cells Nature 2015 528 413 417 10.1038/nature16140 26649828 139. Coffelt SB Wellenstein MD de Visser KE Neutrophils in cancer: neutral no more Nat Rev Cancer 2016 16 431 446 10.1038/nrc.2016.52 27282249 140. Singhal S Bhojnagarwala PS O'Brien S Moon EK Garfall AL Rao AS Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer Cancer Cell 2016 30 120 135 10.1016/j.ccell.2016.06.001 27374224 141. Massara M Bonavita O Savino B Caronni N Mollica Poeta V Sironi M ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity Nat Commun 2018 9 676 10.1038/s41467-018-03080-8 29445158 142. Ponzetta A Carriero R Carnevale S Barbagallo M Molgora M Perucchini C Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors Cell 2019 178 346–60 e24 143. Janiszewska M Tabassum DP Castaño Z Cristea S Yamamoto KN Kingston NL Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments Nat Cell Biol 2019 21 879 888 10.1038/s41556-019-0346-x 31263265 144. Rath J, Bajwa G, Carreres B, Hoyer E, Gruber I, Martínez-Paniagua M, et al. Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4 T cells. Sci Adv. 2020;6:eaaz7809. 145. Nirschl CJ Suárez-Fariñas M Izar B Prakadan S Dannenfelser R Tirosh I IFNγ-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment Cell 2017 170 127–41 e15 146. Wang D Lin J Yang X Long J Bai Y Yang X Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies J Hematol Oncol 2019 12 42 10.1186/s13045-019-0730-9 31014381 147. Topalian SL Drake CG Pardoll DM Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 2015 27 450 461 10.1016/j.ccell.2015.03.001 25858804 148. Zhao Z Zheng L Chen W Weng W Song J Ji J Delivery strategies of cancer immunotherapy: recent advances and future perspectives J Hematol Oncol 2019 12 126 10.1186/s13045-019-0817-3 31779642 149. Sharma P Hu-Lieskovan S Wargo JA Ribas A Primary, adaptive, and acquired resistance to cancer immunotherapy Cell 2017 168 707 723 10.1016/j.cell.2017.01.017 28187290 150. Mahoney KM Rennert PD Freeman GJ Combination cancer immunotherapy and new immunomodulatory targets Nat Rev Drug Discov 2015 14 561 584 10.1038/nrd4591 26228759 151. Yi M Yu S Qin S Liu Q Xu H Zhao W Gut microbiome modulates efficacy of immune checkpoint inhibitors J Hematol Oncol 2018 11 47 10.1186/s13045-018-0592-6 29580257 152. Snyder A Makarov V Merghoub T Yuan J Zaretsky JM Desrichard A Genetic basis for clinical response to CTLA-4 blockade in melanoma N Engl J Med 2014 371 2189 2199 10.1056/NEJMoa1406498 25409260 153. Li Z Song W Rubinstein M Liu D Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing J Hematol Oncol 2018 11 142 10.1186/s13045-018-0684-3 30577797 154. Le DT Uram JN Wang H Bartlett BR Kemberling H Eyring AD PD-1 blockade in tumors with mismatch-repair deficiency N Engl J Med 2015 372 2509 2520 10.1056/NEJMoa1500596 26028255 155. Topalian SL Taube JM Anders RA Pardoll DM Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy Nat Rev Cancer 2016 16 275 287 10.1038/nrc.2016.36 27079802 156. Jiang P Gu S Pan D Fu J Sahu A Hu X Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response Nat Med 2018 24 1550 1558 10.1038/s41591-018-0136-1 30127393 157. Sehgal K Portell A Ivanova E Lizotte P Mahadevan N Greene J Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade J Clin Invest 2020 10.1172/JCI135038 33151910 158. Zilionis R Engblom C Pfirschke C Savova V Zemmour D Saatcioglu HD Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species Immunity 2019 50 1317 1334 10.1016/j.immuni.2019.03.009 30979687 159. Zhang L Li Z Skrzypczynska KM Fang Q Zhang W O'Brien SA Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer Cell 2020 181 442 459 10.1016/j.cell.2020.03.048 32302573 160. Katzenelenbogen Y Sheban F Yalin A Yofe I Svetlichnyy D Jaitin DA Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer Cell 2020 182 872 885 10.1016/j.cell.2020.06.032 32783915 161. Jiang T Shi T Zhang H Hu J Song Y Wei J Tumor neoantigens: from basic research to clinical applications J Hematol Oncol 2019 12 93 10.1186/s13045-019-0787-5 31492199 162. McGranahan N Furness AJ Rosenthal R Ramskov S Lyngaa R Saini SK Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade Science 2016 351 1463 1469 10.1126/science.aaf1490 26940869 163. Hacohen N Fritsch EF Carter TA Lander ES Wu CJ Getting personal with neoantigen-based therapeutic cancer vaccines Cancer Immunol Res 2013 1 11 15 10.1158/2326-6066.CIR-13-0022 24777245 164. Ott PA Hu Z Keskin DB Shukla SA Sun J Bozym DJ An immunogenic personal neoantigen vaccine for patients with melanoma Nature 2017 547 217 221 10.1038/nature22991 28678778 165. Nathanson T Ahuja A Rubinsteyn A Aksoy BA Hellmann MD Miao D Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade Cancer Immunol Res 2017 5 84 91 10.1158/2326-6066.CIR-16-0019 27956380 166. Safonov A Jiang T Bianchini G Győrffy B Karn T Hatzis C Immune gene expression is associated with genomic aberrations in breast cancer Cancer Res 2017 77 3317 3324 10.1158/0008-5472.CAN-16-3478 28428277 167. Karasaki T Nagayama K Kuwano H Nitadori JI Sato M Anraku M Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing Cancer Sci 2017 108 170 177 10.1111/cas.13131 27960040 168. Nejo T Matsushita H Karasaki T Nomura M Saito K Tanaka S Reduced neoantigen expression revealed by longitudinal multiomics as a possible immune evasion mechanism in glioma Cancer Immunol Res 2019 7 1148 1161 10.1158/2326-6066.CIR-18-0599 31088845 169. Lv JW Zheng ZQ Wang ZX Zhou GQ Chen L Mao YP Pan-cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types J Pineal Res 2019 66 e12557 10.1111/jpi.12557 30638277 170. Linxweiler M Kuo F Katabi N Lee M Nadeem Z Dalin MG The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype Clin Cancer Res 2020 26 2859 2870 10.1158/1078-0432.CCR-19-3758 32060100 171. Kim S Kim HS Kim E Lee MG Shin EC Paik S Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information Ann Oncol 2018 29 1030 1036 10.1093/annonc/mdy022 29360924 172. Wang TY Wang L Alam SK Hoeppner LH Yang R ScanNeo: identifying indel-derived neoantigens using RNA-Seq data Bioinformatics 2019 35 4159 4161 10.1093/bioinformatics/btz193 30887025 173. Zhang Z Zhou C Tang L Gong Y Wei Z Zhang G ASNEO: Identification of personalized alternative splicing based neoantigens with RNA-seq Aging (Albany NY) 2020 12 14633 14648 10.18632/aging.103516 32697765 174. Yang H Sun L Guan A Yin H Liu M Mao X Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma Cancer Immunol Immunother 2020 10.1007/s00262-020-02711-8 33237349 175. Lu YC Zheng Z Robbins PF Tran E Prickett TD Gartner JJ An efficient single-cell RNA-seq approach to identify neoantigen-specific T cell receptors Mol Ther 2018 26 379 389 10.1016/j.ymthe.2017.10.018 29174843 176. Engström P Steijger T Sipos B Grant G Kahles A Rätsch G Systematic evaluation of spliced alignment programs for RNA-seq data Nat Methods 2013 10 1185 1191 10.1038/nmeth.2722 24185836 177. Sharon D Tilgner H Grubert F Snyder M A single-molecule long-read survey of the human transcriptome Nat Biotechnol 2013 31 1009 1014 10.1038/nbt.2705 24108091 178. Quail MA Smith M Coupland P Otto TD Harris SR Connor TR A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers BMC Genomics 2012 13 341 10.1186/1471-2164-13-341 22827831 179. Tilgner H Grubert F Sharon D Snyder MP Defining a personal, allele-specific, and single-molecule long-read transcriptome Proc Natl Acad Sci USA 2014 111 9869 9874 10.1073/pnas.1400447111 24961374 180. Stark R Grzelak M Hadfield J RNA sequencing: the teenage years Nat Rev Genet 2019 20 631 656 10.1038/s41576-019-0150-2 31341269 181. Antipov D Korobeynikov A McLean J Pevzner P hybridSPAdes: an algorithm for hybrid assembly of short and long reads Bioinformatics 2016 32 1009 1015 10.1093/bioinformatics/btv688 26589280 182. Boluki S Zamani Dadaneh S Qian X Dougherty E Optimal clustering with missing values BMC Bioinform 2019 20 321 10.1186/s12859-019-2832-3 183. Hicks S Townes F Teng M Irizarry R Missing data and technical variability in single-cell RNA-sequencing experiments Biostatistics 2018 19 562 578 10.1093/biostatistics/kxx053 29121214 184. Hou W Ji Z Ji H Hicks S A systematic evaluation of single-cell RNA-sequencing imputation methods Genome biol 2020 21 218 10.1186/s13059-020-02132-x 32854757 185. Song F Chan G Wei Y Flexible experimental designs for valid single-cell RNA-sequencing experiments allowing batch effects correction Nat Commun 2020 11 3274 10.1038/s41467-020-16905-2 32612268 186. Buenrostro J Giresi P Zaba L Chang H Greenleaf W Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position Nat Methods 2013 10 1213 1218 10.1038/nmeth.2688 24097267 187. Yang C, Ma L, Xiao D, Ying Z, Jiang X, Lin Y. Sparassis latifolia Integration of ATAC-Seq and RNA-Seq Identifies Key Genes in Light-Induced Primordia Formation of. Int J Mol Sci. 2019;21. 188. Wu X, Yang Y, Zhong C, Guo Y, Wei T, Li S, et al. Epinephelus coioides Integration of ATAC-seq and RNA-seq Unravels Chromatin Accessibility during Sex Reversal in Orange-Spotted Grouper (Epinephelus coioides). Int J Mol Sci. 2020;21. 189. Simonis M Kooren J de Laat W An evaluation of 3C-based methods to capture DNA interactions Nat Methods 2007 4 895 901 10.1038/nmeth1114 17971780 190. Lieberman-Aiden E van Berkum N Williams L Imakaev M Ragoczy T Telling A Comprehensive mapping of long-range interactions reveals folding principles of the human genome Science 2009 326 289 293 10.1126/science.1181369 19815776 191. Mifsud B Tavares-Cadete F Young A Sugar R Schoenfelder S Ferreira L Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C Nat Genet 2015 47 598 606 10.1038/ng.3286 25938943 192. Crane E Bian Q McCord R Lajoie B Wheeler B Ralston E Condensin-driven remodelling of X chromosome topology during dosage compensation Nature 2015 523 240 244 10.1038/nature14450 26030525 193. Chen H Seaman L Liu S Ried T Rajapakse I Chromosome conformation and gene expression patterns differ profoundly in human fibroblasts grown in spheroids versus monolayers Nucleus 2017 8 383 391 10.1080/19491034.2017.1280209 28129029 194. Vara C Paytuví-Gallart A Cuartero Y Le Dily F Garcia F Salvà-Castro J Three-dimensional genomic structure and cohesin occupancy correlate with transcriptional activity during spermatogenesis Cell Rep 2019 28 352–67 e9 195. Zeng C Huang W Li Y Weng H Roles of METTL3 in cancer: mechanisms and therapeutic targeting J Hematol Oncol 2020 13 117 10.1186/s13045-020-00951-w 32854717 196. Jenjaroenpun P Wongsurawat T Wadley T Wassenaar T Liu J Dai Q Decoding the epitranscriptional landscape from native RNA sequences Nucleic Acids Res 2020 10.1093/nar/gkaa620 32710622 197. Parker M, Knop K, Sherwood A, Schurch N, Mackinnon K, Gould P, et al. Nanopore direct RNA sequencing maps the complexity of Arabidopsis mRNA processing and mA modification. eLife. 2020;9. 198. Zhang S Li R Zhang L Chen S Xie M Yang L New insights into Arabidopsis transcriptome complexity revealed by direct sequencing of native RNAs Nucleic Acids Res 2020 48 7700 7711 10.1093/nar/gkaa588 32652016 199. Pan X Zhang H Xu D Chen J Chen W Gan S Identification of a novel cancer stem cell subpopulation that promotes progression of human fatal renal cell carcinoma by single-cell RNA-seq analysis Int J Biol Sci 2020 16 3149 3162 10.7150/ijbs.46645 33162821 200. Li Y Chen C Chen J Lai Y Wang S Jiang S Single-cell analysis reveals immune modulation and metabolic switch in tumor-draining lymph nodes Oncoimmunology 2020 9 1830513 10.1080/2162402X.2020.1830513 33117603 201. Giladi A Cohen M Medaglia C Baran Y Li B Zada M Dissecting cellular crosstalk by sequencing physically interacting cells Nat Biotechnol 2020 38 629 637 10.1038/s41587-020-0442-2 32152598 202. Caruso F, Garofano L, D'Angelo F, Yu K, Tang F, Yuan J, et al. A map of tumor-host interactions in glioma at single-cell resolution. GigaScience. 2020;9. 203. Jaitin D Weiner A Yofe I Lara-Astiaso D Keren-Shaul H David E Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNA-seq Cell 2016 167 1883 1896 10.1016/j.cell.2016.11.039 27984734 204. Datlinger P Rendeiro A Schmidl C Krausgruber T Traxler P Klughammer J Pooled CRISPR screening with single-cell transcriptome readout Nat Methods 2017 14 297 301 10.1038/nmeth.4177 28099430 205. Genga R Kernfeld E Parsi K Parsons T Ziller M Maehr R Single-cell RNA-sequencing-based CRISPRi screening resolves molecular drivers of early human endoderm development Cell Rep 2019 27 708 718 10.1016/j.celrep.2019.03.076 30995470 206. Qiu Q Hu P Qiu X Govek K Cámara P Wu H Massively parallel and time-resolved RNA sequencing in single cells with scNT-seq Nat Methods 2020 17 991 1001 10.1038/s41592-020-0935-4 32868927 207. McFarland J Paolella B Warren A Geiger-Schuller K Shibue T Rothberg M Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action Nat commun 2020 11 4296 10.1038/s41467-020-17440-w 32855387 208. Sun W Dong H Balaz M Slyper M Drokhlyansky E Colleluori G snRNA-seq reveals a subpopulation of adipocytes that regulates thermogenesis Nature 2020 587 98 102 10.1038/s41586-020-2856-x 33116305